2024
Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
Patel K, Lansky A, Kelbæk H, Xu B, van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A, Investigators T. Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial). The American Journal Of Cardiology 2024, 217: 94-101. PMID: 38350507, DOI: 10.1016/j.amjcard.2023.12.002.Peer-Reviewed Original ResearchChronic coronary syndromeAcute coronary syndromeTarget lesion failureSirolimus-eluting stentsEverolimus-eluting stentIschemia-driven target lesion revascularizationTarget lesion revascularizationCoronary syndromeDefinite/probable stent thrombosisStent thrombosisClinical presentationLesion revascularizationFIREHAWK stentAcute coronary syndrome presentationSpectrum of clinical presentationsAcute coronary syndrome populationXIENCE stentAcute coronary syndrome cohortLong-term PCI outcomesLong-term outcomesLong-term safetyOpen-labelPatient-oriented outcomesBaseline characteristicsAdverse events
2023
Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial
Patel K, Lansky A, Kelbaek H, Xu B, Van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A. Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial. European Heart Journal 2023, 44: ehad655.1494. DOI: 10.1093/eurheartj/ehad655.1494.Peer-Reviewed Original ResearchAcute coronary syndromeChronic coronary syndromeProbable stent thrombosisCoronary syndromeStent thrombosisFIREHAWK stentLesion failureClinical presentationLong-term PCI outcomesPatient-oriented composite endpointTarget lesion revascularisationMajor adverse eventsLong-term outcomesLong-term safetyCCS cohortComer patientsID-TLRLesion revascularisationCCS patientsOpen labelAdverse eventsBaseline characteristicsACS cohortComposite endpointComers trialEffects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality A Meta-Analysis
Navarese E, Lansky A, Farkouh M, Grzelakowska K, Bonaca M, Gorog D, Raggi P, Kelm M, Yeo B, Umińska J, Curzen N, Kubica J, Wijns W, Kereiakes D. Effects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality A Meta-Analysis. JACC Cardiovascular Interventions 2023, 16: 1144-1156. PMID: 37225285, DOI: 10.1016/j.jcin.2023.02.030.Peer-Reviewed Original ResearchConceptsChronic coronary syndromeElective coronary revascularizationNoncardiac mortalityMedical therapyCoronary revascularizationTrial sequential analysisCumulative Z-curveRate ratioA Meta-AnalysisRandom-effects modelMeta-analysis findingsCoronary syndromeISCHEMIA trialRandomized trialsTrial evidenceRevascularizationTreatment groupsPrespecified endpointsMeta-AnalysisPatientsMortalityFutility boundariesDeath rateTrialsTreatment effectsThe Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy
Hussain Y, Saito S, Curtis M, Kereiakes D, Baumbach A, Zidar J, McLaurin B, Dib N, Smits P, Díaz V, Cequier Á, Hofma S, Pietras C, Dressler O, Issever M, Windecker S, Leon M, Lansky A, Investigators I. The Supreme Biodegradable Polymer DES in Acute and Chronic Coronary Syndromes: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 100629. PMID: 39130696, PMCID: PMC11307614, DOI: 10.1016/j.jscai.2023.100629.Peer-Reviewed Original ResearchTarget lesion failureAcute coronary syndromeChronic coronary syndromePrimary end pointCoronary syndromeDP-EESClinical presentationMajor adverse cardiac eventsEnd pointAdverse cardiac eventsBiodegradable polymer DESPrevious revascularizationLesion failureCardiac eventsCurrent smokersIII trialsLess diabetesCCS groupStent thrombosisPatientsRelative safetyDurable polymerSyndromeMonthsInteraction P
2022
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Patel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. PMID: 39130138, PMCID: PMC11308031, DOI: 10.1016/j.jscai.2021.100004.Peer-Reviewed Original ResearchDrug-eluting stentsTarget lesion failureDP-EESComplex lesionsLesion failureAdverse eventsLesion complexityMajor adverse cardiac eventsSingle-blind clinical trialEnd pointAdverse cardiac eventsChronic coronary syndromePrimary end pointSecondary end pointsTarget lesion revascularizationTarget vessel failureComplex coronary lesionsPercutaneous coronary interventionEverolimus-eluting stentsDrug eluting stentsHigh rateLesion revascularizationCoronary syndromeCardiac eventsCoronary intervention
2021
SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL
Lansky A, Saito S, Curtis M, Kereiakes D, Baumbach A, Bertolet B, Zidar J, McLaurin B, Dib N, Smits P, Diaz V, Cequier A, Hofma S, Pietras C, Windecker S, Leon M. SIMILAR OUTCOMES WITH THE SUPREME™BIODEGRADABLE DRUG COATED CORONARY STENT SYSTEM IN ACUTE CORONARY SYNDROME AND CHRONIC CORONARY SYNDROMES: RESULTS OF THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED PIONEER III TRIAL. Journal Of The American College Of Cardiology 2021, 77: 1211. DOI: 10.1016/s0735-1097(21)02570-5.Peer-Reviewed Original ResearchNovel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease. Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.Peer-Reviewed Original ResearchConceptsDurable polymer everolimus-eluting stentsDrug-eluting stentsTarget lesion revascularizationAntiproliferative drug deliveryChronic coronary syndromeVessel myocardial infarctionLesion revascularizationCoronary syndromeLesion failureMyocardial infarctionDrug-Eluting Stent ImplantationTarget vessel myocardial infarctionLong-term clinical outcomesDP-EES groupPrimary end pointTarget lesion failureSmooth muscle cell proliferationPercutaneous coronary interventionSingle-blind trialCoronary artery diseaseEverolimus-eluting stentsMuscle cell proliferationLong-term inflammatory responseDrug eluting stentsCardiovascular deathDifferential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy. Catheterization And Cardiovascular Interventions 2021, 99: 357-365. PMID: 33502809, DOI: 10.1002/ccd.29468.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyTarget lesion failureDrug-eluting stentsTarget vessel myocardial infarctionBiodegradable polymer drug-eluting stentsChronic coronary syndromeAcute coronary syndromeDAPT discontinuationVessel myocardial infarctionAntiplatelet therapyCoronary syndromeMyocardial infarctionDurable polymer drug-eluting stentsIschemia-driven target lesion revascularizationIschemic coronary artery diseaseTarget lesion revascularizationIschemia-driven revascularizationPercutaneous coronary interventionCoronary artery diseaseIschemic coronary diseaseComer studyLesion revascularizationDAPT durationLesion failurePrimary endpoint
2020
Does the operator's sex matter? An analysis based on the national interventional cardiology registry.
Lanocha M, Lansky A, Siudak Z, Włodarczak A, Tarchalski J, Malinowski KP, Laskowski W, Sikora T, Radziszewska E, Dolecka-Ślusarczyk M, Wojakowski W, Bartuś S, Grygier M, Tokarek T, Dudek D, Lesiak M. Does the operator's sex matter? An analysis based on the national interventional cardiology registry. Kardiologia Polska 2020, 78: 1221-1226. PMID: 33146499, DOI: 10.33963/kp.15665.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionPractice patternsOutcomes of PCIInterventional cardiologyInterventional Cardiology RegistryCardiovascular risk factorsAcute coronary syndromeSingle-vessel diseaseCoronary artery interventionInvasive cardiology proceduresSex matterMale operatorsCardiology RegistryCoronary syndromeCoronary interventionArtery interventionMore patientsClinical outcomesMain indicationsNational registryRisk factorsMedian numberContrast dosesLow prevalenceHigh dosesTCT CONNECT-208 Accuracy of Quantitative Coronary Angiography and Visual Assessment for Predicting Functionally Significant Stenoses in Women With Chronic Coronary Syndrome
Gitto M, Taoutel R, Schneider M, Papoutsidakis N, Ardito S, Cristea E, Lansky A, Altin S. TCT CONNECT-208 Accuracy of Quantitative Coronary Angiography and Visual Assessment for Predicting Functionally Significant Stenoses in Women With Chronic Coronary Syndrome. Journal Of The American College Of Cardiology 2020, 76: b88. DOI: 10.1016/j.jacc.2020.09.223.Peer-Reviewed Original ResearchTCT CONNECT-206 SPECT Stress Testing Versus Contrast-Flow Coronary QFR for Ischemia Detection in Women Presenting With Chronic Coronary Syndromes
Taoutel R, Gitto M, Saito Y, Schneider M, Ardito S, Papoutsidakis N, Cristea E, Shaddinger D, Lansky A, Altin S. TCT CONNECT-206 SPECT Stress Testing Versus Contrast-Flow Coronary QFR for Ischemia Detection in Women Presenting With Chronic Coronary Syndromes. Journal Of The American College Of Cardiology 2020, 76: b87. DOI: 10.1016/j.jacc.2020.09.221.Peer-Reviewed Original Research
2019
Validation of the all-comers design: Results of the TARGET-AC substudy
G Toth G, Lansky A, Baumbach A, Kelbæk H, van Royen N, Holmvang L, Janssens L, Brugaletta S, Barbato E, Maillard L, Kiemeneij F, Naber CK, Pucher F, Laursen PN, Ameloot K, Robles C, Milkas A, Sevilla J, Jensen C, Wijns W. Validation of the all-comers design: Results of the TARGET-AC substudy. American Heart Journal 2019, 221: 148-154. PMID: 31924299, DOI: 10.1016/j.ahj.2019.10.019.Peer-Reviewed Original ResearchConceptsComers designRisk factorsNon-ST elevation acute coronary syndromeElevation acute coronary syndromeNER groupReal-world clinical practiceGroup more patientsInternational multicentre registrySignificant valvular diseaseST-elevation infarctionAcute coronary syndromeChronic total occlusionWorld clinical practiceLow inclusion rateMulticentre registryThrombotic stenosisCoronary syndromePrimary PCIStable anginaAngiographic parametersComers populationPatient demographicsStable patientsStudy nursesMore patients
2018
Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EuroIntervention 2018, 13: 1554-1560. PMID: 29131802, DOI: 10.4244/eij-d-17-00886.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAcute Coronary SyndromeAdultClinical Decision-MakingCoronary Artery DiseaseCoronary ThrombosisFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPractice Patterns, Physicians'Product Surveillance, PostmarketingProspective StudiesProsthesis DesignRegistriesRisk FactorsTime FactorsTreatment OutcomeUnited KingdomConceptsBioresorbable vascular scaffoldDe novo coronary lesionsOne-year clinical outcomesIndependent clinical events committeeMajor adverse cardiac eventsAbsorb bioresorbable vascular scaffoldCareful implantation techniqueAdverse cardiac eventsNovo coronary lesionsTarget lesion failureAcute coronary syndromeClinical events committeeB2/CCareful patient selectionContemporary drug-eluting stentsDrug-eluting stentsVascular scaffoldsSmall vessel sizeDefinite STCoronary syndromeLesion failureCardiac eventsPatient ageReal-world practiceBVS implantation
2016
Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study
Kedhi E, Kennedy MW, Maehara A, Lansky AJ, McAndrew TC, Marso SP, De Bruyne B, Serruys PW, Stone GW. Impact of TCFA on Unanticipated Ischemic Events in Medically Treated Diabetes Mellitus Insights From the PROSPECT Study. JACC Cardiovascular Imaging 2016, 10: 451-458. PMID: 27372016, DOI: 10.1016/j.jcmg.2015.12.023.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDiabetes MellitusDisease ProgressionFemaleFibrosisHumansMaleMiddle AgedPercutaneous Coronary InterventionPlaque, AtheroscleroticPredictive Value of TestsPropensity ScoreRisk FactorsRupture, SpontaneousTime FactorsTreatment OutcomeUltrasonography, InterventionalConceptsMajor adverse cardiac eventsAcute coronary syndromeThin-cap fibroatheromaNonculprit lesionsDiabetes mellitusACS patientsDM patientsSubsequent major adverse cardiac eventsPresence of DMPROSPECT studyAdverse cardiac eventsPropensity-matched groupsRadiofrequency intravascular ultrasoundHigh rateCoronary syndromeCardiac eventsPlaque compositionIntravascular ultrasoundPatientsPropensity scoreBalanced groupsIschemicMellitusFibroatheromaPrognosisSignificance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry.
Iñiguez A, Brener SJ, Jiménez VA, Maehara A, Mintz GS, Xu K, Weisz G, Lansky AJ, De Bruyne B, Serruys PW, Stone GW. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: insights from the prospective PROSPECT registry. EuroIntervention 2016, 11: 1468-74. PMID: 27107311, DOI: 10.4244/eijv11i13a285.Peer-Reviewed Original ResearchConceptsPrior PCIPrior percutaneous coronary interventionMajor adverse cardiac eventsACS patientsAcute coronary syndrome patientsAdverse cardiac eventsAcute coronary syndromeChronic kidney diseaseCoronary syndrome patientsHigh-risk featuresCongestive heart failureIntravascular ultrasound findingsPercutaneous coronary interventionPrior myocardial infarctionCoronary syndromeCardiac eventsCoronary interventionCardiac deathHeart failurePercutaneous revascularisationKidney diseaseMyocardial infarctionUltrasound findingsIndependent associationMultivariable model
2015
Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials
Brener SJ, Mehran R, Lansky AJ, Ayele GM, Stone GW. Pretreatment with aspirin in acute coronary syndromes: Lessons from the ACUITY and HORIZONS-AMI trials. European Heart Journal Acute Cardiovascular Care 2015, 5: 449-454. PMID: 26722003, DOI: 10.1177/2048872615624848.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeHORIZONS-AMI trialCoronary syndromeAspirin pretreatmentMyocardial infarctionCardiac deathStent thrombosisSegment elevation acute coronary syndromesST-segment elevation myocardial infarctionElevation acute coronary syndromeAcute coronary syndrome patientsLarge randomized clinical trialsAdverse ischemic eventsTarget vessel revascularizationCoronary syndrome patientsIndependent risk factorElevation myocardial infarctionLarge prospective studiesHigh-risk cohortIncidence of deathRandomized clinical trialsMultivariable regression analysisPrior revascularizationVessel revascularizationIschemic eventsImpact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials)
Ng VG, Baumbach A, Grinfeld L, Lincoff AM, Mehran R, Stone GW, Lansky AJ. Impact of Bleeding and Bivalirudin Therapy on Mortality Risk in Women Undergoing Percutaneous Coronary Intervention (from the REPLACE-2, ACUITY, and HORIZONS-AMI Trials). The American Journal Of Cardiology 2015, 117: 186-191. PMID: 26704028, DOI: 10.1016/j.amjcard.2015.10.029.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionStrong independent predictorMajor bleedingMortality rateBivalirudin therapyCoronary interventionIndependent predictorsFemale genderGlycoprotein IIb/IIIa inhibitor treatmentST-segment elevation myocardial infarctionNon-coronary artery bypassPatient-level pooled analysisImpact of bleedingMajor bleeding ratesPronounced clinical benefitOutcomes of patientsAcute coronary syndromeCohort of patientsElevation myocardial infarctionArtery bypassCoronary syndromeMultivariate adjustmentStandard therapyClinical benefitPooled analysisPrognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome.
Hassanin A, Brener SJ, Lansky AJ, Xu K, Stone GW. Prognostic impact of multivessel versus culprit vessel only percutaneous intervention for patients with multivessel coronary artery disease presenting with acute coronary syndrome. EuroIntervention 2015, 11: 293-300. PMID: 25136882, DOI: 10.4244/eijy14m08_05.Peer-Reviewed Original ResearchConceptsMV-percutaneous coronary interventionMajor adverse cardiac eventsPercutaneous coronary interventionAcute coronary syndromeIschaemia-driven revascularisationMyocardial infarctionNSTE-ACSCoronary syndromeMV diseaseOne-year major adverse cardiac eventsPeriprocedural non-Q-wave myocardial infarctionSegment elevation acute coronary syndromesNon-Q-wave myocardial infarctionDeath/myocardial infarctionElevation acute coronary syndromeMultivessel coronary artery diseaseUrgent Intervention Triage StrategyMultivessel percutaneous coronary interventionMV-PCI groupAdverse cardiac eventsAcute renal failureCoronary artery diseaseOne-year ratesClear clinical benefitPropensity score adjustment
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleedingRelation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study)
Kelly CR, Weisz G, Maehara A, Mintz GS, Mehran R, Lansky AJ, Parise H, de Bruyne B, Serruys PW, Stone GW. Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from the PROSPECT Study). The American Journal Of Cardiology 2014, 114: 376-383. PMID: 24931291, DOI: 10.1016/j.amjcard.2014.04.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCoronary AngiographyCoronary Artery DiseaseC-Reactive ProteinDisease ProgressionFemaleGlobal HealthHumansIncidenceInflammationMaleMiddle AgedPlaque, AtheroscleroticPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexSurvival RateTime FactorsConceptsMajor adverse cardiac eventsC-reactive protein levelsNonculprit lesionsElevated CRP levelsCRP levelsVulnerable coronary plaquesIntravascular ultrasoundCoronary plaquesPost-acute coronary syndrome patientsSubsequent major adverse cardiac eventsGray-scale intravascular ultrasoundCoronary Tree (PROSPECT) studyUntreated nonculprit lesionsAdverse cardiac eventsAdverse coronary eventsAcute coronary syndromeCoronary syndrome patientsPercutaneous coronary interventionRadiofrequency intravascular ultrasoundPredictors of eventsProtein levelsMinimal luminal areaHigh rateCoronary eventsCoronary syndrome